Bausch Health Cos (BHC) Set to Announce Earnings on Wednesday

Bausch Health Cos (NYSE:BHC) is anticipated to release its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect Bausch Health Cos to post earnings of $1.25 per share and revenue of $2.72 billion for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 5:00 PM ET.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. The business had revenue of $2.83 billion for the quarter, compared to the consensus estimate of $2.59 billion. On average, analysts expect Bausch Health Cos to post $4.35 EPS for the current fiscal year and $4.02 EPS for the next fiscal year.

Bausch Health Cos Trading Down 1.5%

BHC opened at $6.34 on Tuesday. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -2.14 and a beta of 0.37. Bausch Health Cos has a 1 year low of $4.33 and a 1 year high of $8.00. The stock has a fifty day moving average price of $6.17 and a 200 day moving average price of $5.72.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BHC. Zacks Research raised Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 21st. Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $9.00 price objective on shares of Bausch Health Cos in a research note on Thursday, October 8th. Finally, Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Insiders Place Their Bets

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of Bausch Health Cos stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the transaction, the insider owned 334,853 shares in the company, valued at approximately $2,354,016.59. The trade was a 9.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by corporate insiders.

Bausch Health Cos Company Profile

Bausch Health Companies Inc (NYSE:BHC) is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations.